Botulinum toxin versus trihexyphenidyl in cervical dystonia: A prospective, randomized, double-blind controlled trial

Neurology

Volumn 46, Issue 4, 1996, Pages 1066-1072

  Brans, J W M ^a,e   Lindeboom, R ^a   Snoek, J W ^b   Zwarts, M J ^b   Van Weerden, T W ^c   Brunt, E R P ^c   Van Hilten, J J ^d   Van Der Kamp, W ^d   Prins, M H ^a   Speelman, J D ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Department of Neurology ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; TRIHEXYPHENIDYL;

ADULT; AMNESIA; ARTICLE; CERVICAL SPINE INJURY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSTONIA; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TORTICOLLIS; TREATMENT OUTCOME; XEROSTOMIA;

EID: 9244220100     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.4.1066     Document Type: Article

References (33)

1. Podivinsky F, Torticollis. In: Vinken PJ, Bruyn GW, eds. Handbook of clinical neurology: diseases of the basal ganglia. 6th ed. Amsterdam: North Holland Publishing Company, 1968:567-603.
2. Jayne D, Lees AJ, Stern GM. Remission in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1984;47:1236-1237.
3. Friedman A, Fahn S. Spontaneous remissions in spasmodic torticollis. Neurology 1986;36:398-400.
4. Lowenstein DH, Aminoff MJ. The clinical course of spasmodic torticollis. Neurology 1988;38:530-532.
5. Jahanshahi M, Marion MH, Marsden CD. Natural history of adult-onset idiopathic torticollis. Arch Neurol 1990;47:548-552.
6. Rondot P, Marchand MP, Dellatolas G. Spasmodic torticollis: review of 220 patients. Can J Neurol Sci 1991;18:143-151.
7. Jankovic J, Leder S, Warner D, Schwartz KS. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991;41:1088-1091.
8. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991;6:119-126.
9. Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ III. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988;3:188-194.
10. Tsui JKC, Eisen A, Mak E, Carruthers J, Scott AB, Calne DB. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 1985;12:314-316.
11. Cullis PA, Walker PC. The treatment of spasmodic torticollis. In: Quinn NP, Jenner PG, eds. Disorders of movement. San Diego: Academic Press, 1989:295-301.
12. Lang AE. Drug treatment of dystonia. In: Quinn NP, Jenner PG, eds. Disorders of movement. San Diego: Academic Press, 1989:313-321.
13. Jabbari B, Scherokman B, Gunderson CH, Rosenberg ML, Miller J. Treatment of movement disorders with trihexyphenidyl. Mov Disord 1989;3:202-212.
14. Fahn S. High-dosage anticholinergic therapy in dystonia. Neurology 1983;33:1255-1261.
15. Greene PE, Shale HM, Fahn S. Experience with high-dosage of anticholinergic and other drugs in the treatment of torsion dystonia. Adv Neurol 1988;50:547-556.
16. Lang AE. High-dose anticholinergic therapy in adult dystonia. Can J Neurol Sci 1986;13:42-46.
17. Greene PE, Shale HM, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 1988;3:46-60.
18. Marsden CD, Marion M-H, Quinn N. The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry 1984;47:1166-1173.
19. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-1194.
20. Tsui JKC, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245-246.
21. Gelb DJ, Lowenstein DH, Aminoff MJ. Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 1989;39:80-84.
22. Koller W, Vetere-Overfield B, Gray C, Dubinsky R. Failure of fixed-dose, fixed muscle injections of botulinum toxin in torticollis. Clin Neuropharmacol 1990;13:355-358.
23. Blackie JD, Lees AJ. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1992;53:640-643.
24. Greene PE, Kang UJ, Fahn S, Brin MF, Moskowitz CB, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990;40:1213-1218.
25. Lorentz IT, Subramaniam SS, Yiannikas C. Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients. Mov Disord 1991;6: 145-150.
26. Moore AP, Blumhardt LD. A double-blind trial of botulinum toxin A in torticollis, with one year follow-up. J Neurol Neurosurg Psychiatry 1991;54:813-816.
27. Consky E, Basinski A, Belle L, Ranawaya R, Lang AE. The Toronto Western Spasmodic Torticollis Rating Scale (TW-STRS). Neurology 1990;40(suppl 1):445.
28. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, Inc, 1994:211-237.
29. Altman DG. Clinical trials. In: Altman DG, ed. Practical statistics for medical research. London: Chapman & Hall, 1993: 440-476.
30. Brans JWM, de Boer IP, Aramideh M, Ongerboer de Visser BW, Speelman JD. Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance. J Neurol 1995;242: 529-534.
31. Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988;26:724-735.
32. Anonymous. International Classification of Impairments, Disabilities and Handicaps. Geneva: World Health Organization, 1980.
33. Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986;36:160-164.